reports
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Wim Hoste
- Mathijs Geerts Danau
mdxhealth FIRST LOOK: FY25 highlights show revenue in line with guidan...
Mdxhealth provides insights into key FY25 parameters, with preliminary revenue landing at $ 109m (VA CSS: $ 108.5m) and YE cash at $ 29m (VA CSS: $ 34.5m). Revenue guidance for FY26 is set at a narrow yet ambitious range of $ 137-140m, implying a 26-28% y/y increase. Additionally, mdxhealth managed to amend the Exact Sciences payouts to be more back-end loaded bringing some ease to the cash position. We believe that mdxhealth is well-positioned for growth in 2026 now that the commercial engine i...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenu...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA – January 12, 2026 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2025 revenues and issued 2026 revenue guidance. The Company expects to report fourth quarter and full yea...
- Jacob Mekhael
mdxhealth Collaboration with Oxford could further validate GPS in pros...
Yesterday before US market opens, mdxhealth announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). This study is designed to establish GPS as the first genomic classifier supported by randomised clinical trial evidence in an Active Surveillance cohort, further validating the clinical utility of GPS in predicting prostate cancer progressi...
- Jacob Mekhael
- Livio Luyten
Mdxhealth and University of Oxford to validate GPS test in largest ran...
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 () – Mdxhealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the l...
- Mathijs Geerts Danau
mdxhealth 3Q25 results continue adj. EBITDA profitability, guidance ma...
Yesterday evening mdxhealth reported 3Q25 results. The company had $ 27.4m in revenue up 18% y/y, with a gross margin of 65.2% representing a 4% improvement. OPEX was essentially flat leading to a second quarter of adj. EBITDA profitability of $ 1m. The company reiterated its FY25 revenue guidance and reported that it will fully focus on integrating the ExoDx acquisition into the business in the 4Q25. Therefore, it will postpone Germline and re-evaluate the opportunity in 2026. We reiterate our ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Mdxhealth Reports Results for the Third Quarter and Nine-Month Period...
Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 Q3 revenues increased by 18% to $27.4 millionAdjusted EBITDA profitability of $1.0 million for Q3Acquisition of ExoDx business from Bio-Techne CorporationConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA – November 12, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the three and ...
Mdxhealth to Release Third Quarter 2025 Financial Results on November ...
Mdxhealth to Release Third Quarter 2025 Financial Results on November 12 Mdxhealth to Release Third Quarter 2025 Financial Resultson November 12 Company to Host Conference Call with Live Q&A, November 12, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – November 3, 2025 () – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2025, after market close on Wednesday, November 12, 2025. Title:Mdxhealth Presents Third Quarter 2025 Financial Results andCorporate Update Conference...
- Jacob Mekhael
- Mathijs Geerts Danau
Life Sciences Conference 25 Sep 2025
KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.
Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bi...
Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne IRVINE, CA, and HERSTAL, BELGIUM – September 15, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the closing of the ExoDx business acquisition from Bio-Techne Corporation, which includes the ExoDx Prostate test. Acquisition of ExoDx Business On August 5, 2025, mdxhealth signed a definitive agreement to acquire Exosome Diagnostics, Inc. from Bio-Techne, i...
- Jacob Mekhael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Pos...
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 millionAdjusted EBITDA profitability of $1.4 million for Q2 Agreement to acquire ExoDx Business from Bio-Techne for $15 million in cash and stock over 5 years; acquisition expected to accelerate revenue growt...
- Hilde Van Boxstael
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
Mdxhealth Appoints Michael Holder to Board of Directors and Announces...
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and pr...
- Thomas Vranken
mdxhealth 1Q25 results emphasize tissue-based growth, adj. EBITDA on t...
mdxhealth reported 1Q25 results, showing $ 24.3m rev (+22% y/y), driven primarily by a 41% rise in tissue-based test volumes. Company is clearly prioritizing the opportunity in tissue-based with higher ASP and margins, as tandem Confirm/GPS is well received by urology practices and pathology labs. Gross margins made a resulting 3 ppt jump y/y to 63.8% while opex remained largely in line, leading to adj. EBITDA of $ -1.3m. Mgmt reiterated its FY25 revenue guidance of $ 108-110m and confirmed it i...
- Hilde Van Boxstael
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
MDxHealth Reports Q1-2025 Results
MDxHealth Reports Q1-2025 Results Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: “mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% o...
Mdxhealth to Release First Quarter 2025 Financial Results on May 14
Mdxhealth to Release First Quarter 2025 Financial Results on May 14 Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 () – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Fin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.